IPO - PALATIN TECHNOLOGIES INC

Form Type: 424B4

Filing Date: 2025-05-08

Corporate Action: Ipo

Type: New

Accession Number: 000165495425005297

Filing Summary: On May 8, 2025, Palatin Technologies Inc. filed a prospectus for an IPO, offering 7,324,119 shares of Common Stock alongside Series F and G Common Warrants. Each share is priced at $0.15, with a combined offering expected to yield approximately $1,021,714.60 before expenses. The Series F Warrants have an exercise price of $0.30, while Series G Warrants are priced at $0.15. The offering is engaged through A.G.P./Alliance Global Partners as the lead placement agent. Significant risks include potential non-compliance with NYSE American listing requirements and uncertainties regarding future financing. Delivery of the securities is scheduled on or about May 8, 2025. The offering will terminate on May 30, 2025. Investors should review risks associated with the investment carefully, as there's no guarantee that the offering will fully meet financial objectives. The company's ability to maintain listing on NYSE American is currently in jeopardy due to historical non-compliance.

Form Type: S-1

Filing Date: 2025-03-31

Corporate Action: Ipo

Type: New

Accession Number: 000165495425003691

Filing Summary: Palatin Technologies, Inc., a biopharmaceutical company, filed a registration statement under the Securities Act of 1933 on March 31, 2025, in preparation for an initial public offering (IPO) of its securities. The company is offering up to 17,317,816 shares of its common stock alongside common warrants and pre-funded warrants. The combined public offering price for each share of common stock and accompanying common warrant was initially set at $0.7218, based on the market closing price prior to the offering. The prospectus outlines certain aspects of the company's financial status and its ongoing efforts in drug development, particularly focusing on products utilizing the melanocortin receptor system to treat various diseases including obesity and dry eye disease. The company acknowledges operational challenges and risks, notably the uncertainty of achieving profitability and maintaining compliance with NYSE listing standards. Significant details include the engagement of A.G.P./Alliance Global Partners and Laidlaw & Company as the Placement Agents, the anticipated use of proceeds from the offering, and the need for substantial additional financing to continue operations. The offering is set to terminate on April 25, 2025, unless otherwise decided by the company.

Form Type: DRS

Filing Date: 2025-03-07

Corporate Action: Ipo

Type: New

Accession Number: 000165495425002400

Filing Summary: Palatin Technologies, Inc. is planning to offer up to 16,666,667 shares of common stock and related Series F common warrants, alongside pre-funded warrants in a proposed public offering. The offering’s estimated public offering price is $0.90 per share, based on the recent closing price of its common stock on NYSE American. The company will engage A.G.P. and Laidlaw as placement agents. The securities being offered are subject to various conditions, including a continuous offering under Rule 415. The cash fees payable to the placement agents are set at 7.0% of the aggregate purchase price paid by investors. The company states that it has significant operating losses and expresses concern for future financing. With no minimum offering amount required, there’s uncertainty about proceeds and business goals. The company also acknowledges compliance issues with NYSE American listing requirements and is actively working on plans for regaining compliance. This IPO is aimed at raising capital for its product development initiatives, particularly for pharmaceuticals targeting significant unmet medical needs. Investors are advised to consider associated risks thoroughly before participating.